Potent and selective breast tumor kinase (Brk, also known as tyrosine-protein kinase 6, PTK6) inhibitor (IC50
= 3.15 nM). Exhibits >1000-fold selectivity for Brk over a panel of other kinases. Inhibits proliferation of breast cancer cells in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from Martin-Luther-Universität-Halle-Wittenburg
Discovery of 4-anilino α-carbolines as novel Brk inhibitors.
Mahmoud et al.